Other than that, aflibercept, also known as ziv-aflibercept, ramucirumab, and regorafenib were also approved by the FDA as the anti-VEGF antibodies to treat CRC (Grothey et al., 2013; Ohishi et al., 2023). The gene discussed is VEGFA; the disease is colorectal carcinoma.